Details of the Drug-Related molecule(s) Interaction Atlas

Acemetacin Drug Info

Acemetacina; Acemetacina [INN-Spanish]; Acemetacine; Acemetacine [INN-French]; Acemetacinum; Acemetacinum [INN-Latin]; Acemix; Aximeixin; Emflex; Rantudil; Rheumibis; TVX 3322; indometacin carboxymethyl ester; indometacin glycolic ester; indomethacin carboxymethyl ester; indomethacin glycolic ester; 1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-, carboxymethyl ester; 53164-05-9; BRN 0501672; Bay f 4975; C21H18ClNO6; CHEBI:31162; CHEMBL189171; EINECS 258-403-4; K 708; K-708; UNII-5V141XK28X; acemetacin

Cross-matching ID

PubChem CID

1981

ChEBI ID

CHEBI:31162

CAS Number

CAS 53164-05-9

TTD Drug ID

DML6CN4

INTEDE Drug ID

DR0035

General Information of Drug (ID: DML6CN4)

Molecule-Related Drug Atlas

Molecule Type:

DME

Drug Status:

Approved Drug(s)

Download the Complete Related Drug List

Drug(s) Metabolized By UDP-glucuronosyltransferase 2B7 (UGT2B7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[2]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[3]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[4]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[5]
Mycophenolate mofetil	DMPQAGE	Hepatosplenic T-cell lymphoma		Approved	[6]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[4]
PITAVASTATIN CALCIUM	DM1UJO0	Dyslipidemia	5C80-5C81	Approved	[7]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[8]
Ezetimibe	DM7A8TW	Atherosclerosis	BD40	Approved	[9]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
UDP-glucuronosyltransferase 2B7 (UGT2B7)^{Main DME}	DEB3CV1	UD2B7_HUMAN	Substrate	[1]

------------------------------------------------------------------------------------

References

1	Seyffart G. (1992). Drug dosage in renal insufficiency (2nd ed.). Springer Science+Business Media Dordrecht.
2	Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy. Future Oncol. 2014 Jan;10(1):107-22.
3	Determination of UDP-glucuronosyltransferase UGT2B7 activity in human liver microsomes by ultra-performance liquid chromatography with MS detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Jul 1;870(1):84-90.
4	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
5	Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects. Clin Pharmacol Ther. 2008 Apr;83(4):595-600.
6	PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
7	Pitavastatin: a review in hypercholesterolemia. Am J Cardiovasc Drugs. 2017 Apr;17(2):157-168.
8	Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10. Drug Metab Dispos. 2002 Dec;30(12):1462-9.
9	Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet. 2005;44(5):467-94.
10	Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med. 2016 Oct 3;9:97-106.